In 2015, Hebei Guogao biotechnology company was established to build an enzyme-linked immunosorbent assay platform.

Who passed the medical device medical management system in May 2018 and obtained two product registration certificates of myocardial infarction, cerebral infarction and heart failure.

The system assessment of seven varieties of fluorescence immunochromatography was carried out in November 2019.

Seven product registration approvals were obtained in January 2020.

Ten product registration approvals were obtained in September 2021.

A total of 200 approvals are expected in 2023.